Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study Evaluating ZX-101A in Patients with Relapsed/Refractory Hematological Malignancies

NCT05269940 is registered in ClinicalTrials.gov with Nanjing Zenshine Pharmaceuticals as lead sponsor.

NCT NCT05269940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05269940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study Evaluating ZX-101A in Patients with Relapsed/Refractory Hematological Malignancies
Lead sponsor
Nanjing Zenshine Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
February 17, 2022
Completion date
July 5, 2024
Enrollment
40 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cll/sll, non hodgkin lymphoma, peripheral t cell lymphoma